Private Equity 3 Days

Last updated: May 16, 2026, 5:31 PM ET

Deal Activity & Sector Focus Closed merger saw Charlesbank‑backed Tecomet combine with Orchid Orthopedic Solutions, creating a unified medical‑device platform under the Tecomet name and expanding its European footprint. In parallel, Kinderhook completed take‑private of Enhabit Home Health & Hospice, adding a $1.2bn revenue business to its long‑term care portfolio and positioning the firm for consolidation in the fragmented home‑health market. Both transactions underscore private equity’s push into healthcare services, where stable cash flows and demographic tailwinds are driving higher valuation multiples.

Geographic Expansion & Capital Deployment Exited China fund disclosed that Schroders will transfer its wholly‑owned China fund unit to Neuberger Berman, marking a retreat from direct on‑shore asset management in Beijing amid tightening regulatory scrutiny. Meanwhile, CPP Investments committed €400m alongside Blackstone to acquire a minority stake in French last‑mile logistics platform Proudreed, reflecting growing appetite for European e‑commerce fulfilment assets as cross‑border trade rebounds. These moves illustrate a broader rebalancing, with sovereign and mega‑funds redeploying capital toward logistics and market‑neutral strategies while shedding exposure to politically sensitive regions.

Debt‑Heavy Restructurings Engineered debt cut revealed that a consortium led by Blackstone and KKR will restructure Affordable Care Services, writing off roughly 70% of its $2.4bn debt load and converting the remainder into equity, effectively handing the lenders control of the Medicaid‑focused provider. The deal highlights how private equity is leveraging distressed‑debt expertise to acquire critical‑infrastructure operators at deep discounts, a trend amplified by heightened credit stress in the healthcare sector.

Life‑Science & Technology Investments Targeted life‑science firms reported that Blackstone, Audax and Five Arrows are scouting pharmaceutical and life‑science consulting targets, citing rising R&D complexity as a catalyst for platform builds. In a related move, Eir Partners invested in QuartzBio, a data‑analytics specialist that promises to accelerate drug discovery pipelines, signalling that PE firms are increasingly betting on niche tech that de‑risks late‑stage development. These activities suggest a shift from pure capital infusion toward building vertically integrated service ecosystems that capture higher-margin advisory fees.

Mid‑Market Buyouts & Fundraising Welsh Carson targeted $5bn for its 15th flagship vehicle focused on North‑American mid‑market buyouts, reflecting strong LP appetite for stable, cash‑flow businesses after a year of volatile public markets. At the same time, Meridian Ventures launched $35m fund aimed at MBA‑deferred founders building enterprise technology, indicating that niche, founder‑friendly capital is emerging alongside traditional large‑cap buyout funds. The dual trend of sizable flagship raises and boutique seed‑stage vehicles points to a widening spectrum of capital sources across the private‑equity continuum.

Secondary Market Dynamics CV pricing rose as buyside demand intensified, pushing the average pricing of secondary transactions toward the upper end of the valuation band and compressing discount levels. Concurrently, Evercore added senior infra talent from Campbell Lutyens, bolstering its capabilities in infrastructure secondaries where asset‑heavy portfolios are increasingly traded to meet liquidity needs. The tightening of secondary pricing and talent inflows signal a maturing market where investors are willing to pay premium for high‑quality, cash‑generating assets, further fueling the overall fundraising environment.